КУРКУМА В ЛЕЧЕНИИ ПСОРИАЗА: ПЕРВЫЕ УСПЕХИ

Mikhail Ivanovich Musatov


Аннотация


Многочисленные клинические испытания последних 25 лет при многих заболеваниях человека были посвящены исследованию биодоступности, безопасности и эффективности куркуминоидов, главного компонента куркумы (Curcuma longa). Однако первое клиническое испытание (2008 г) при бляшковидном псориазе было досрочно прекращено как неэффективное, поскольку авторы использовали бионедоступную форму куркуминоидов.

Целью настоящего обзора был поиск и обсуждение результатов клинических испытаний биодоступных форм куркуминоидов при бляшковидном псориазе.

Как источник данных до 2015 г. включительно использовалась база PubMed Национальной медицинской библиотеки США.

Анализ опубликованных данных позволяет сделать вывод о перспективности использования биодоступных форм куркуминоидов для системного или местного лечения псориаза как в виде монотерапии, так и в сочетании с принятыми методами лечения.


Ключевые слова


Curcuma Longa; куркумин; куркуминоиды; псориаз; клинические испытания

Полный текст:

PDF>PDF

Литература


National Psoriasis Foungation. Annual Report 2015. URL: https://www.psoriasis.org/sites/default/files/2015_annualreport_for_web.pdf (дата обращения 20.12.2015).

Afifi T., Huang Ch. Topical therapies for psoriasis. Evidence-based review. Can. Fam. Physician, 2005, vol. 51, no 4. Рp. 519–525.

Yang X., Zheng S.G. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev, 2014, vol. 13, no. 6. Рp. 615–620.

Sun J., Zhao Yi., Hu J. Curcumin Inhibits Imiquimod-Induced Psoriasis-Like Inflammation by Inhibiting IL-1beta and IL-6 Production in Mice. PLoS One, 2013, vol. 8, no. 6. Published online 2013 Jun 25. Doi: 10.1371/journal.pone.0067078.

Farkas A., Kemeny L. (2012) Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle. Int Immunopharmacol, 2012, vol. 13. Рp. 215–218.

Govindarajan V. S. Turmeric chemistry, technology and quality. CRC Rev. Food Sci. Nutr, 1980, vol. 12. Рp. 199–301.

Gupta C.S., Patchva S., Aggarwal B.B. Therapeutic Roles of Curcumin: Lessons Learned from Clinical trials. The AAPS Journal, 2013, vol. 15, no. 1. Рp. 195–218.

Le Beau M.M., Ito C, Cogswell P., Espinosa R., Fernald A. A., Baldwin A. S. Jr. Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively. Genomics, 1992, vol.14, no 2. Рp. 529–531.

Lin Y.G., Kunnumakkara A.B., Nair A, Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappa B pathway. Clin Cancer Res, 2007, vol. 13. Рp. 3423–3430.

Shishodia S. Molecular mechanisms of curcumin action: gene expression. Biofactors, 2013, vol. 39, no. 1. Рp. 37–55.

Hu A., Huang J.J., Jin X.J., Li J.P., Tang Y.J., Huang X.F., Cui H.J., Xu W.H., Sun G.B. Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. Am J Cancer Res, 2014, Dec vol. 5, no. 1. Рp. 278–88.

Seyung S., Vadgama C., Vadgama J.V. Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-regulation of STAT3–NFĸB Signaling. Anticancer Res, 2015, vol. 35. Рp. 39–46.

Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as “Curecumin”: from kitchen to clinic Biochem. Pharmacol,. 2008, vol. 75, no. 4. Рp. 787–809.

Niazi J., Poonia P., Gupta V., Kaur N. Pharmacotherapeutics of Curcuma Longa – a Potent Patent. Int. J. Pharma Professional’s Res, 2010, vol. 1, no.1. Рp. 24–33.

Trujillo J., Chirino Y. I., Molina-Jijón E., Andérica-Romero A.C. a, Tapia E., Pedraza-Chaverrí J. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol, 2013, vol. 1, no. 1. Рp. 448–456.

Cruz-Correa M., Shoskes D.A., Sanchez P., Zhao R., Hylind L.M., Wexner S.D. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol, 2006, vol. 4, no. 8. Рp. 1035–1038.

Prasad S., Tyagi A.K., Aggarwal B.B. Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice. Cancer Res. Treat., 2014, vol. 46, no. 1. Рp. 2–18.

Cuomo J., Appendino G., Dern A.S., Schneider E., McKinnon T.P., Brown M.J., Togni S., Dixon B.M. Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation. J. Nat. Prod, 2011, vol. 74, no. 4. Рp. 664–669.

Di Silvestro R.A., Joseph E., Shi Zhao, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutrition Journal, 2012. 11:79. 8 Pages. doi:10.1186/1475-2891-11-79.

Liu Chi-Hsien., Huang Hsin-Ying. Antimicrobial Activity of Curcumin-Loaded Myristic Acid Microemulsions against Staphylococcus epidermidis. Chem. Pharm. Bull, 2012, vol. 60, no. 9. Рp. 1118–1124.

Kurd S.K., Smith N., VanVoorhees A., Troxel A.B., Badmaev V., Seykora J.T., Gelfand J.M. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J. Am. Acad. Dermatol, 2008, vol. 58. Рp. 625–631.

Feldman S.R., Krueger G.G. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis, 2005. vol. 64, Suppl. II. Рp. 65–68.

Cuomo J., Appendino G., Dern A.S., Schneider E., McKinnon T.P., Brown M.J., Togni S., Dixon B.M. Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation. J. Nat. Prod, 2011. vol. 74, no. 4. Рp. 664–669.

Antiga E., Bonciolini V., Volpi W., Del Bianco E., Caproni M. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. BioMed. Research International, vol. 2015, Article ID 283634, 7 pages, http://dx.doi.org/10.1155/2015/283634.

Sarafian, G., Afshar M., Mansouri P., Asgarpanah J., Raoufinejad K., Rajabi M. Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation. Iran. J. Pharm. Res, 2015, vol.14, no. 3. Рp. 865–876.

Becker D., Langer E., Seemann M., Seemann G., Fell I., Saloga J., Grabbe S., von Stebutet E. Clinical Efficacy of Blue Light Full Body Irradiation as Treatment Option for Severe Atopic Dermatitis. PLoS ONE, 2011, vol.6, no. 6: e20566. doi:10.1371/journal.pone.0020566.

Bernd A. Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin. Phytochem. Rev, 2014, vol. 13. Рp. 183–189.

Niu T., Tian Y., Cai Q., Ren Q., Wei L. (2015) Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin. PLoS ONEI, 2015, vol. 10, no. 9: e0138754. doi:10.1371/journal.pone.0138754.

Carrion-Gutierrez M., Ramirez-Bosca A., Navarro-Lopez V., Martinez-Andres A., Asín-Llorca M., Bernd A., Horga de la Parte J.F. Effects of Curcuma extract and visible light on adults with plaque psoriasis. Eur. J. Dermatol, 2015, vol. 25, no. 3. Рp. 240–246.

Ramirez-Boscá A., Soler A., Carrión-Gutiérrez M.A., Pamies M,D., Pardo Z.J., Diaz-Alperi J., Bernd A., Quintanilla A.E., Miquel J. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech. Ageing Dev, 2000, vol. 114, no. 3. Рp. 207–210.




DOI: https://doi.org/10.12731/wsd-2016-2-4

Ссылки

  • На текущий момент ссылки отсутствуют.


Bookmark and Share


(c) 2016 В мире научных открытий



ISSN 2658-6649 (print)

ISSN 2658-6657 (online)

HotLog Яндекс цитирования